Providence Financial Advisors LLC Acquires Shares of 6,117 Johnson & Johnson $JNJ

Providence Financial Advisors LLC acquired a new stake in shares of Johnson & Johnson (NYSE:JNJ) in the third quarter, HoldingsChannel reports. The fund acquired 6,117 shares of the company’s stock, valued at approximately $1,134,000. Johnson & Johnson accounts for approximately 1.1% of Providence Financial Advisors LLC’s holdings, making the stock its 13th largest position.

A number of other institutional investors have also modified their holdings of JNJ. Abich Financial Wealth Management LLC acquired a new stake in Johnson & Johnson during the third quarter valued at approximately $26,000. Evolution Wealth Management Inc. acquired a new stake in shares of Johnson & Johnson during the 2nd quarter valued at approximately $27,000. Clayton Financial Group LLC bought a new position in Johnson & Johnson during the third quarter worth $28,000. Semmax Financial Advisors Inc. lifted its stake in Johnson & Johnson by 55.0% during the second quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock worth $31,000 after purchasing an additional 72 shares during the last quarter. Finally, Compass Financial Services Inc boosted its holdings in Johnson & Johnson by 707.1% in the third quarter. Compass Financial Services Inc now owns 226 shares of the company’s stock worth $42,000 after purchasing an additional 198 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $243.37 on Monday. The stock has a fifty day moving average of $217.25 and a 200-day moving average of $196.79. The company has a market capitalization of $586.51 billion, a PE ratio of 22.02, a price-to-earnings-growth ratio of 2.36 and a beta of 0.35. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.77 and a current ratio of 1.03. Johnson & Johnson has a one year low of $141.50 and a one year high of $246.35.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Saturday, January 31st. The company reported $2.46 earnings per share for the quarter. The business had revenue of $24.28 billion during the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%. As a group, equities analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th will be given a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 2.1%. The ex-dividend date of this dividend is Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio (DPR) is 47.06%.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on JNJ shares. Weiss Ratings reiterated a “buy (b)” rating on shares of Johnson & Johnson in a research note on Wednesday, January 28th. HSBC raised their price objective on shares of Johnson & Johnson from $240.00 to $265.00 and gave the company a “buy” rating in a research note on Friday, January 30th. Freedom Capital downgraded Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 16th. Daiwa Securities Group lifted their price target on Johnson & Johnson from $203.00 to $237.00 and gave the company an “outperform” rating in a research report on Thursday, January 29th. Finally, Wolfe Research upped their price objective on Johnson & Johnson from $225.00 to $240.00 and gave the company an “outperform” rating in a report on Monday, January 5th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $233.73.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Jim Cramer publicly praised J&J on-air, calling the company “amazing,” which can boost retail investor interest and provide short-term support for the stock. Johnson & Johnson (JNJ) Is Amazing, Says Jim Cramer
• Neutral Sentiment: Wall Street Zen cut JNJ to a Hold, signaling reduced upside conviction from at least one boutique research provider; that can temper buying enthusiasm but is not a major institutional downgrade. Johnson & Johnson (NYSE:JNJ) Cut to Hold at Wall Street Zen
• Negative Sentiment: A Pennsylvania jury found J&J liable in a talc/ovarian-cancer case and ordered $250,000 in damages to the family of Gayle Emerson — a reminder that ongoing talc litigation continues to create legal costs, uncertainty and headline risk for the company. Jury: Johnson & Johnson Liable in Case Linking Baby Powder to Cancer

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.